Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...
The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...
With a market cap of around $730 billion, Eli Lilly (NYSE: LLY) is one of the largest pharmaceutical companies on planet ...
14d
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss ...
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...
Eli Lilly (NYSE: LLY) has been on a tear for the better part of the last decade, but the company has experienced a bit of a ...
The Daily Overview on MSN
Trump vows to slash obesity drug prices as pharma stocks drop
On October 17, 2025, President Donald Trump announced his intention to implement significant price reductions for obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback